{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T05:20:31Z","timestamp":1741324831590,"version":"3.38.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,6]]},"DOI":"10.7759\/cureus.80156","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T17:51:50Z","timestamp":1741283510000},"source":"Crossref","is-referenced-by-count":0,"title":["Drug Price and Health Policy Knowledge Influence Prescription Behavior in Orphan Diseases: Pheochromocytoma and Paraganglioma As Prototypes of Orphan Drug Econometrics"],"prefix":"10.7759","author":[{"given":"Danny Q","family":"Le","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany N","family":"Burton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian J","family":"Tejeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe C","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason S","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirav","family":"Kamdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002191","article-title":"What is the purpose of the Orphan Drug Act?","volume":"14","author":"Herder M","year":"2017","unstructured":"Herder M. What is the purpose of the Orphan Drug Act?. PLoS Med. 2017, 14:e1002191. 10.1371\/journal.pmed.1002191","journal-title":"PLoS Med"},{"key":"ref2","unstructured":"Department of Health and Human Services. Office of Inspector General. The Orphan Drug Act: Implementation and Impact. (2001). Accessed: 15 June 2022: https:\/\/www.govinfo.gov\/content\/pkg\/GOVPUB-HE-PURL-gpo75081\/pdf\/GOVPUB-HE-PURL-gpo75081.pdf."},{"key":"ref3","article-title":"The Orphan Drug Act at 35: observations and an outlook for the twenty-first century","volume":"19","author":"Bagley","year":"2018","unstructured":"Bagley, N, Benjamin B, Amitabh C, Craig G, Ariel DS. The Orphan Drug Act at 35: observations and an outlook for the twenty-first century. Innov Pol Econ. 2018, 19:97-137.","journal-title":"Innov Pol Econ"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23672","article-title":"Unintended effects of orphan product designation for rare neurological diseases","volume":"72","author":"Murphy SM","year":"2012","unstructured":"Murphy SM, Puwanant A, Griggs RC. Unintended effects of orphan product designation for rare neurological diseases. Ann Neurol. 2012, 72:481-90. 10.1002\/ana.23672","journal-title":"Ann Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0018578719867665","article-title":"The Orphan Drug Act: an appropriate approval pathway for treatments of rare diseases?","volume":"54","author":"Gabay M","year":"2019","unstructured":"Gabay M. The Orphan Drug Act: an appropriate approval pathway for treatments of rare diseases?. Hosp Pharm. 2019, 54:283-4. 10.1177\/0018578719867665","journal-title":"Hosp Pharm"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2017.1179","article-title":"Evaluating the impact of the Orphan Drug Act's seven-year market exclusivity period","volume":"37","author":"Sarpatwari A","year":"2018","unstructured":"Sarpatwari A, Beall RF, Abdurrob A, He M, Kesselheim AS. Evaluating the impact of the Orphan Drug Act's seven-year market exclusivity period. Health Aff (Millwood). 2018, 37:732-7. 10.1377\/hlthaff.2017.1179","journal-title":"Health Aff (Millwood)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.healthpol.2009.12.001","article-title":"The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?","volume":"95","author":"Wellman-Labadie O","year":"2010","unstructured":"Wellman-Labadie O, Zhou Y. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?. Health Policy. 2010, 95:216-28. 10.1016\/j.healthpol.2009.12.001","journal-title":"Health Policy"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.11237","article-title":"The high cost of prescription drugs in the United States: origins and prospects for reform","volume":"316","author":"Kesselheim AS","year":"2016","unstructured":"Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016, 316:858-71. 10.1001\/jama.2016.11237","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.23.10.1066","article-title":"The FDA Unapproved Drugs Initiative: an observational study of the consequences for drug prices and shortages in the United States","volume":"23","author":"Gupta R","year":"2017","unstructured":"Gupta R, Dhruva SS, Fox ER, Ross JS. The FDA Unapproved Drugs Initiative: an observational study of the consequences for drug prices and shortages in the United States. J Manag Care Spec Pharm. 2017, 23:1066-76. 10.18553\/jmcp.2017.23.10.1066","journal-title":"J Manag Care Spec Pharm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-019-00072-8","article-title":"Estimating the impact of Food and Drug Administration's Unapproved Drug Initiative on drug prices and sales","volume":"54","author":"Sharma D","year":"2020","unstructured":"Sharma D, Schumock GT, Saffore CD, Albert Edwards S, Walton SM. Estimating the impact of Food and Drug Administration's Unapproved Drug Initiative on drug prices and sales. Ther Innov Regul Sci. 2020, 54:424-30. 10.1007\/s43441-019-00072-8","journal-title":"Ther Innov Regul Sci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2021.1989","article-title":"Market exclusivity and changes in competition and prices associated with the US Food and Drug Administration Unapproved Drug Initiative","volume":"181","author":"Gunter SJ","year":"2021","unstructured":"Gunter SJ, Kesselheim AS, Rome BN. Market exclusivity and changes in competition and prices associated with the US Food and Drug Administration Unapproved Drug Initiative. JAMA Intern Med. 2021, 181:1124-6. 10.1001\/jamainternmed.2021.1989","journal-title":"JAMA Intern Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.1555","article-title":"Measuring the impact of the Food And Drug Administration (FDA) Unapproved Drug Initiative (UDI) on drug prices and expenditures","volume":"20","author":"Sharma D","year":"2017","unstructured":"Sharma D, Schumock G, Saffore CD, Walton SM. Measuring the impact of the Food And Drug Administration (FDA) Unapproved Drug Initiative (UDI) on drug prices and expenditures. Value Health. 2017, 20:A655. 10.1016\/j.jval.2017.08.1555","journal-title":"Value Health"},{"key":"ref13","unstructured":"Federal Register .: Termination of the Food and Drug Administration's Unapproved Drugs Initiative; Request for Information Regarding Drugs Potentially Generally Recognized as Safe and Effective; Withdrawal. (2021). Accessed: March 6, 2025: https:\/\/www.federalregister.gov\/documents\/2021\/05\/27\/2021-11257\/termination-of-the-food-and-drug-administrations-unap...."},{"key":"ref14","unstructured":"Frequently Asked Questions Regarding the Department of Health and Human Services\u2019 Announcement on the Unapproved Drugs Initiative. (2021). Accessed. June 20, 2022: https:\/\/www.hhs.gov\/sites\/default\/files\/covid-19-unapproved-drugs-initiative.pdf."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2011.02.002","article-title":"Hypertension in pheochromocytoma: characteristics and treatment","volume":"40","author":"Zuber SM","year":"2011","unstructured":"Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma: characteristics and treatment. Endocrinol Metab Clin North Am. 2011, 40:295-311, vii. 10.1016\/j.ecl.2011.02.002","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-6175.2002.01452.x","article-title":"Pheochromocytoma","volume":"4","author":"Manger WM","year":"2002","unstructured":"Manger WM, Gifford RW. Pheochromocytoma. J Clin Hypertens (Greenwich). 2002, 4:62-72. 10.1111\/j.1524-6175.2002.01452.x","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4103\/0970-9185.161665","article-title":"Pheochromocytoma resection: current concepts in anesthetic management","volume":"31","author":"Ramakrishna H","year":"2015","unstructured":"Ramakrishna H. Pheochromocytoma resection: current concepts in anesthetic management. J Anaesthesiol Clin Pharmacol. 2015, 31:317-23. 10.4103\/0970-9185.161665","journal-title":"J Anaesthesiol Clin Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.86977","article-title":"Implications and considerations during pheochromocytoma resection: a challenge to the anesthesiologist","volume":"15 Suppl 4","author":"Bajwa SS","year":"2011","unstructured":"Bajwa SS, Bajwa SK. Implications and considerations during pheochromocytoma resection: a challenge to the anesthesiologist. Indian J Endocrinol Metab. 2011, 15 Suppl 4:S337-44. 10.4103\/2230-8210.86977","journal-title":"Indian J Endocrinol Metab"},{"key":"ref19","article-title":"Pheochromocytoma: a review on preoperative treatment with phenoxybenzamine or doxazosin","volume":"72","author":"van der Zee PA","year":"2014","unstructured":"van der Zee PA, de Boer A. Pheochromocytoma: a review on preoperative treatment with phenoxybenzamine or doxazosin. Neth J Med. 2014, 72:190-201.","journal-title":"Neth J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5514-7","article-title":"Selective versus non-selective \u03b1-blockade prior to laparoscopic adrenalectomy for pheochromocytoma","volume":"24","author":"Randle RW","year":"2017","unstructured":"Randle RW, Balentine CJ, Pitt SC, Schneider DF, Sippel RS. Selective versus non-selective \u03b1-blockade prior to laparoscopic adrenalectomy for pheochromocytoma. Ann Surg Oncol. 2017, 24:244-50. 10.1245\/s10434-016-5514-7","journal-title":"Ann Surg Oncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz188","article-title":"Efficacy of \u03b1-blockers on hemodynamic control during pheochromocytoma resection: a randomized controlled trial","volume":"105","author":"Buitenwerf E","year":"2020","unstructured":"Buitenwerf E, Osinga TE, Timmers HJ, et al.. Efficacy of \u03b1-blockers on hemodynamic control during pheochromocytoma resection: a randomized controlled trial. J Clin Endocrinol Metab. 2020, 105:2381-91. 10.1210\/clinem\/dgz188","journal-title":"J Clin Endocrinol Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1053\/j.jvca.2017.02.023","article-title":"Perioperative management of pheochromocytoma","volume":"31","author":"Naranjo J","year":"2017","unstructured":"Naranjo J, Dodd S, Martin YN. Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth. 2017, 31:1427-39. 10.1053\/j.jvca.2017.02.023","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.06.013","article-title":"Comparison of preoperative alpha-blockade for resection of paraganglioma and pheochromocytoma","volume":"28","author":"Zhu CY","year":"2022","unstructured":"Zhu CY, Hong JC, Kamdar NV, et al.. Comparison of preoperative alpha-blockade for resection of paraganglioma and pheochromocytoma. Endocr Pract. 2022, 28:889-96. 10.1016\/j.eprac.2022.06.013","journal-title":"Endocr Pract"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4158\/1934-2403-25.2.200","article-title":"A necessity, not a second thought: pre-operative alpha-adrenoceptor blockade in pheochromocytoma patients","volume":"25","author":"Santos JR","year":"2019","unstructured":"Santos JR, Wolf KI, Pacak K. A necessity, not a second thought: pre-operative alpha-adrenoceptor blockade in pheochromocytoma patients. Endocr Pract. 2019, 25:200-1. 10.4158\/1934-2403-25.2.200","journal-title":"Endocr Pract"},{"key":"ref25","unstructured":"Lantheus to Discontinue Production of Azedra. (2023). Accessed. February 2, 2023: https:\/\/snmmi.org\/Web\/News\/Articles\/Lantheus-to-Discontinue-Production-of-Azedra.aspx."},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2409427","article-title":"Rapid cardiovascular response to belzutifan in HIF2A-mediated paraganglioma","volume":"391","author":"Alkaissi H","year":"2024","unstructured":"Alkaissi H, Nazari MA, Hadrava Vanova K, et al.. Rapid cardiovascular response to belzutifan in HIF2A-mediated paraganglioma. N Engl J Med. 2024, 391:1552-5. 10.1056\/NEJMc2409427","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1700244","article-title":"Nitroprusside and isoproterenol use after major price increases","volume":"377","author":"Khot UN","year":"2017","unstructured":"Khot UN, Vogan ED, Militello MA. Nitroprusside and isoproterenol use after major price increases. N Engl J Med. 2017, 377:594-5. 10.1056\/NEJMc1700244","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/320431-drug-price-and-health-policy-knowledge-influence-prescription-behavior-in-orphan-diseases-pheochromocytoma-and-paraganglioma-as-prototypes-of-orphan-drug-econometrics","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T17:51:55Z","timestamp":1741283515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/320431-drug-price-and-health-policy-knowledge-influence-prescription-behavior-in-orphan-diseases-pheochromocytoma-and-paraganglioma-as-prototypes-of-orphan-drug-econometrics"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.80156","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,6]]}}}